Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Daiichi Sankyo commences enrolment for cancer drug trial

Daiichi Sankyo commences enrolment for cancer drug trial

14th January 2011

Daiichi Sankyo has begun recruiting patients for a forthcoming clinical trial of ARQ 197, the non-small cell lung cancer (NSCLC) drug it is developing with ArQule.

The companies have enrolled their first subject for the phase III study, which will evaluate the developmental selective inhibitor of the c-Met receptor tyrosine kinase in combination with erlotinib.

Its primary endpoint will be to assess the drug's efficacy in delivering overall survival benefits compared to placebo, while secondary assessment criteria include progression-free survival rates.

Dr Kazunori Hirokawa, global head of research and development at Daiichi Sankyo, expressed hope that this trial will support the positive data gleaned from earlier phase II studies.

"We are very pleased to begin this phase III trial to advance the knowledge about the role ARQ 197 might have in the treatment of patients with NSCLC in combination with erlotinib," he added.

Last month, the company announced that it has received regulatory clearance in Germany for the blood pressure drug Sevikar HCT, representing its first European approval.ADNFCR-8000103-ID-800342516-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.